Trial Profile
A Double-Blind, Randomized, Phase III, Parallel Group Study Evaluating the Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Isotretinoin (Primary)
- Indications Nodulocystic acne
- Focus Registrational; Therapeutic Use
- Sponsors Cipher Pharmaceuticals
- 02 Dec 2015 According to the Sun Pharma media release, based on the data of this trial NDA was approved for Absorica (Isotretinoin).
- 19 Sep 2014 New trial record